CLINICAL TRIAL: NEW ONSET OF TYPE 1 DIABETES ANTI-CD20 CLINICAL TRIAL

$874M01FY2009RRNIH

University Of Maryland Baltimore, Baltimore MD

Investigators

Linked publications & trials

Paper 39131916 Paper 39115956 Paper 38935492 Paper 38757788 Paper 38583756 Paper 38477777 Paper 38435069 Paper 38266973 Paper 38212425 Paper 38105137 Paper 38103719 Paper 37889527 Paper 37741609 Paper 37717847 Paper 37717845 Paper 37616058 Paper 37609990 Paper 37441488 Paper 37429030 Paper 37205602 Paper 37100172 Paper 37014015 Paper 36814088 Paper 36738890 Paper 36288905 Paper 36100915 Paper 35902682 Paper 35810825 Paper 35777833 Paper 35746879 Paper 35716955 Paper 35510527 Paper 35444055 Paper 35372819 Paper 35343329 Paper 35226897 Paper 35145041 Paper 35007146 Paper 34788785 Paper 34763078 Paper 34697628 Paper 34656710 Paper 34597264 Paper 34465608 Paper 34339746 Paper 34293394 Paper 34195833 Paper 34175376 Paper 34169199 Paper 34052355 Paper 34029681 Paper 33857532 Paper 33735863 Paper 33732981 Paper 33661286 Paper 33479519 Paper 33462081 Paper 33421453 Paper 33402679 Paper 33326030 Paper 33309860 Paper 33306688 Paper 33301877 Paper 33177074 Paper 33163721 Paper 33161774 Paper 33122288 Paper 33089138 Paper 33023926 Paper 32973085 Paper 32866540 Paper 32798563 Paper 32781942 Paper 32768632 Paper 32664108 Paper 32578483 Paper 32576601 Paper 32503932 Paper 32387023 Paper 32317121 Paper 32217634 Paper 32205410 Paper 32146126 Paper 32082553 Paper 31891001 Paper 31864822 Paper 31732235 Paper 31673705 Paper 31668375 Paper 31578216 Paper 31445926 Paper 31235617 Paper 31146814 Paper 31088582 Paper 30935773 Paper 30910373 Paper 30887029 Paper 30776971 Paper 30596171 Paper 30510134

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is testing Rituximab, a drug that alters the immune system in patients newly diagnosed with Type 1 diabetes to see if continued destruction of insulin-producing cells in the pancreas can be halted. Patients will receive the four infusions of Rituximab at another center, and then the rest of the study related visits will take place at UMB GCRC.

View original record on NIH RePORTER →